The stock of INmune Bio Inc (INMB) has gone down by -7.14% for the week, with a -18.87% drop in the past month and a -39.87% drop in the past quarter. The volatility ratio for the week is 6.05%, and the volatility levels for the past 30 days are 6.11% for INMB. The simple moving average for the past 20 days is -16.88% for INMB’s stock, with a -45.34% simple moving average for the past 200 days.
Is It Worth Investing in INmune Bio Inc (NASDAQ: INMB) Right Now?
The 36-month beta value for INMB is also noteworthy at 1.87. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for INMB is 13.41M, and at present, short sellers hold a 22.50% of that float. The average trading volume of INMB on September 16, 2024 was 184.37K shares.
INMB) stock’s latest price update
INmune Bio Inc (NASDAQ: INMB)’s stock price has gone decline by -14.55 in comparison to its previous close of 6.39, however, the company has experienced a -7.14% decrease in its stock price over the last five trading days. globenewswire.com reported 2024-09-13 that Boca Raton, Florida, Sept. 13, 2024 (GLOBE NEWSWIRE) — INmune Bio Inc. (Nasdaq: INMB) (the “Company” or “INmune Bio”), a clinical-stage inflammation and immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced it has entered into securities purchase agreements with new and existing institutional investors and certain directors and officers and employees of the Company (the directors and officers and employees herein referred to as the “Insiders”), for the purchase and sale of 2,341,260 shares of its common stock and warrants to purchase up to an aggregate of 2,341,260 shares of common stock at a combined purchase price per share and accompanying warrant of $5.50 for the institutional investors, and $6.50 per share and accompanying warrant for the Insiders, pursuant to a registered direct offering. The warrants will be exercisable commencing six months from the date of issuance at a price of $6.40 per share and will expire five years from the initial exercise date. The warrant term may be subject to acceleration following the satisfaction of certain conditions. In the case of Insiders that participated in the offering, if the warrant termination date is on a blackout date, then the Insiders will have an additional 60 days from the termination of the blackout date to exercise the warrant.
Analysts’ Opinion of INMB
Many brokerage firms have already submitted their reports for INMB stocks, with Scotiabank repeating the rating for INMB by listing it as a “Sector Outperform.” The predicted price for INMB in the upcoming period, according to Scotiabank is $22 based on the research report published on August 22, 2024 of the current year 2024.
Robert W. Baird, on the other hand, stated in their research note that they expect to see INMB reach a price target of $16. The rating they have provided for INMB stocks is “Outperform” according to the report published on June 01st, 2023.
B. Riley Securities gave a rating of “Neutral” to INMB, setting the target price at $7 in the report published on May 24th of the previous year.
INMB Trading at -27.33% from the 50-Day Moving Average
After a stumble in the market that brought INMB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.96% of loss for the given period.
Volatility was left at 6.11%, however, over the last 30 days, the volatility rate increased by 6.05%, as shares sank -20.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -31.66% lower at present.
During the last 5 trading sessions, INMB fell by -7.14%, which changed the moving average for the period of 200-days by -41.73% in comparison to the 20-day moving average, which settled at $6.50. In addition, INmune Bio Inc saw -51.51% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at INMB starting from Juda Scott, who purchase 5,000 shares at the price of $7.27 back on Jun 25 ’24. After this action, Juda Scott now owns 71,603 shares of INmune Bio Inc, valued at $36,350 using the latest closing price.
Juda Scott, the Director of INmune Bio Inc, purchase 7,000 shares at $6.95 during a trade that took place back on Nov 10 ’23, which means that Juda Scott is holding 37,000 shares at $48,650 based on the most recent closing price.
Stock Fundamentals for INMB
Current profitability levels for the company are sitting at:
- -444.58 for the present operating margin
- 1.0 for the gross margin
The net margin for INmune Bio Inc stands at -444.02. The total capital return value is set at -1.01. Equity return is now at value -86.04, with -61.78 for asset returns.
Based on INmune Bio Inc (INMB), the company’s capital structure generated 0.13 points at debt to capital in total, while cash flow to debt ratio is standing at -4.24. The debt to equity ratio resting at 0.15. The interest coverage ratio of the stock is 334.42.
Currently, EBITDA for the company is -29.74 million with net debt to EBITDA at 0.68. When we switch over and look at the enterprise to sales, we see a ratio of 969.1. The receivables turnover for the company is 0.02for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.36.
Conclusion
In summary, INmune Bio Inc (INMB) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
